Oslo University Hospital
Oslo, Norway
Location status: Recruiting
Location contact
Kirsten B Holven, Professor
CONTACT
NCT Number: NCT06172335
In this Randomized Controlled Trial (RCT) we want to study the effect of an oil with high concentrations of cetoelic acid (C22:n1-11) (intervention) compared to supplements with a low concentration of cetoleic acid (control), but with equivalent content of EPA og DHA, on plasma levels of epa and dha as well as atherosclerotic markers, glucose, c-peptide and triglycerides in a patient group with a metabolically unfavorable phenotype.
Our primary endpoints are changes in the concentration of EPA and DHA in plasma.
Interested in participating?
Request Info20 year–70 year
All sexes
Interventional
Not applicable
Oslo, Norway
Location status: Recruiting
Kirsten B Holven, Professor
CONTACT
This is a randomized double-blinded controlled trial (randomized 1:1). Study population: men and women 20-70 years with a metabolically unfavorable phenotype defined as: triglycerides > 1.7 mmol/L and waist measurement > 80 cm (women) and > 94 cm (men).
Study design:
The intervention oil is consists of an oil high in cetoleic acid and the control oil is low in cetoleic acid. Both the intervention oil and the control oil are a mix of different oils; fish oils, olive oil, "high-oleic sunflower oil" and rapeseed oil so that the content of EPA, DHA and ALA is similar in the two oils.
Power calculation and sample size:
It was expected a difference of 15% in n-3 between the groups after the intervention (Østbye et al. 2019, doi:10.1017/S0007114519001478).
The level of significance was set to 5% (two-sided) and the power to 80%. A total of thirty-eight subjects were required to participate in the study, but a high dropout rate was expected (20%) and it was considered necessary to include a total of seventy (n=70) subjects (thirty-five per arm).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Very long monounsaturated fatty acid (C22:1n-11)
Mix of oils with low cetoleic acid content
Time frame: 4 weeks intervention
EPA and DHA concentration in plasma measured at baseline and after 4 week intervention (and as a "control measurement" at the screening visit)
Time frame: 4 weeks intervention
Plasma levels of triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, apolipoproteins (apoB and apoA), and Lp(a)
Time frame: 4 weeks intervention
Serum levels of glucose
Time frame: 4 weeks intervention
The concentration of circulating levels of inflammatory markers
Time frame: 4 weeks intervention
Changes in PBMC (peripheral blood mononuclear cell) gene expression profile. Changes in plasma metabolome and lipidome profile. Changes in PBMC epitranscriptome, as a regulator of the gene expression profile
Time frame: 4 weeks intervention
Blood levels of resolvin (omega- 3 derivates) concentration
Time frame: 4 weeks intervention
serum levels of C-peptid
Contact information is provided by the study sponsor or research team.
Iselin S. Holen, MSc
CONTACT
Kirsten B. Holven, PhD
CONTACT
Oslo University Hospital
Other
Effects of Ketolic Acid on Atherosclerosis Markers in High-risk Patients With Metabolic Syndrome (Effekt av Ketolinsyre på aterosklerosemarkører i høyrisikopasienter Med Metabolsk Syndrom)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07728669
Body Weight, Diabetes Mellitus
Almaty, Kazakhstan
View Trial DetailsNCT07411222
Behavior, Bipolar Disorder
Bolu, Turkey (Türkiye)
View Trial DetailsNCT06072963
Alzheimer Disease, Brain Diseases
Ramat Gan, Israel
View Trial DetailsNCT01143480
Arterial Occlusive Diseases, Arteriosclerosis
Research Triangle Park, North Carolina, United States
View Trial Details